Search
Toggle theme
Menu
Back
Home
Publications
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
Public
More options
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
N
Shared by
NobleBlocks
on Feb 1, 2020 • 12:00 AM UTC
Authors:
Jhanelle E. Gray
,
Augusto Villegas
,
Davey Daniel
+17 more
Download PDF
Share
Summary
Sum
PDF
Figures
Figs
Discrepancies
Disc
EDDII
Article
Art
Finding related papers...
Discussions
(0)
Add Comment
No comments yet
Be the first to share your thoughts!
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC | NobleBlocks
